Furfenorex (unde brand name Frugalan), was used against obesity as an appetite suppressant. One of its metabolite was metamphetamine, which lead to the abuse to the drug. That is why this drug is no longer marketed

Furbucillin is a synthetic antibacterial agent that has never been marketed. Information about the current use of this drug is not available.

Furnidipine, a calcium channel blocker was developed as an antihypertensive agent. It participated in clinical trials for the treatment of patients with heart failure, hypertension, and ischemic heart disorders in Spain and in Switzerland. However, all these studies were discontinued.

Furmethoxadone was developed as an antibacterial agent and was studied as an anthelmintic. Information about the current use of this compound is not available.

Furofenac (also known as SAS 650), a drug that has antiplatelet-aggregation activity and anti-inflammatory activity combined with low ulcerogenic power. It was shown that the furofenac mechanism of action involved the modulation of the platelet cyclooxygenase pathway.

The information related to the biological or pharmacological application of fluprednisolone valerate is absent.

Trifenagrel is a potent inhibitor of arachidonate (AA)- and collagen-induced aggregation of platelets from several animal species and humans. When trifenagrel was administered p.o. to guinea pigs, there was a sustained (greater than 3 hr) inhibition of AA- and collagen-induced platelet aggregation ex vivo. In humans, trifenagrel inhibited the second phase of ADP-induced aggregation ex vivo up to 6 hr after a single dose of 100 to 300 mg p.o. The mechanism of action of trifenagrel appears to be a reversible inhibition of platelet AA cyclooxygenase. Although trifenagrel caused gastrointestinal irritation in dogs and humans, the nature of the damage suggests that the compound may have acted as a local irritant in these species. Furthermore, compared to aspirin trifenagrel produced significantly less gastric irritation and fecal blood loss in humans. Trifenagrel was developed for the treatment of ischemic heart disorders. However, this development was discontinued.

Trocimine (N-3,4,5-trimethoxybenzoylheptamethylenimine) is heptamethylenimine derivative with antidepressant activity.

Embusartan or BAY106734 (6-n-butyl-4-methoxycarbonyl-2-oxo-1[(2'-(1H-tetrazol-5-yl) -3-fluorobiphenyl-4-yl)methyl] 1,2-dihydropyridine) is an angiotensin II receptors antagonist. Embusartan has beneficial effects in different animal hypertension models. Embusartan appears as a potent and specific new inhibitor of angiotensin II-induced growth-related events in vascular smooth muscle cells. It was being developed for the treatment of hypertension.

Agouron (Pfizer) was developing AG-24322 (AG-024322), a small-molecule cyclin-dependent kinase (CDK) inhibitor, for the treatment of cancer. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models. AG-24322 is a potent ATP-competitive inhibitor of CDK1, CDK2, and CDK4 with Ki values in the 2–3 nM range and selectivity over other non-CDKs. This compound has been shown to inhibit Rb phosphorylation in cells, elicit cell-cycle arrest, and have antiproliferative activity in multiple human tumor cell lines (IC50 values from 30 to 200 nM). AG-24322 was reported to be undergoing phase I trials for cancer in the US, however the development was discontinued.